Enanta Pharmaceuticals In...
4.94
0.10 (2.07%)
At close: Jan 15, 2025, 10:44 AM

Enanta Pharmaceuticals Statistics

Share Statistics

Enanta Pharmaceuticals has 21.19M shares outstanding. The number of shares has increased by 0.18% in one year.

Shares Outstanding 21.19M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.03%
Owned by Institutions (%) n/a
Shares Floating 19.73M
Failed to Deliver (FTD) Shares 5
FTD / Avg. Volume 0%

Short Selling Information

The latest short interest is 3.44M, so 16.23% of the outstanding shares have been sold short.

Short Interest 3.44M
Short % of Shares Out 16.23%
Short % of Float 17.43%
Short Ratio (days to cover) 20.91

Valuation Ratios

The PE ratio is -1.89 and the forward PE ratio is -2.21.

PE Ratio -1.89
Forward PE -2.21
PS Ratio 3.24
Forward PS 1.5
PB Ratio 1.7
P/FCF Ratio -2.27
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Enanta Pharmaceuticals Inc. has an Enterprise Value (EV) of 175.35M.

EV / Earnings -1.51
EV / Sales 2.59
EV / EBITDA -1.68
EV / EBIT -1.44
EV / FCF -1.81

Financial Position

The company has a current ratio of 5.21, with a Debt / Equity ratio of 0.01.

Current Ratio 5.21
Quick Ratio 5.21
Debt / Equity 0.01
Total Debt / Capitalization 1.17
Cash Flow / Debt -51.68
Interest Coverage -11.12

Financial Efficiency

Return on equity (ROE) is -0.9% and return on capital (ROIC) is -65.06%.

Return on Equity (ROE) -0.9%
Return on Assets (ROA) -0.31%
Return on Capital (ROIC) -65.06%
Revenue Per Employee 466.45K
Profits Per Employee -800.31K
Employee Count 145
Asset Turnover 0.18
Inventory Turnover 0

Taxes

Income Tax -1.74M
Effective Tax Rate 0.01

Stock Price Statistics

The stock price has increased by -56.84% in the last 52 weeks. The beta is 0.57, so Enanta Pharmaceuticals 's price volatility has been higher than the market average.

Beta 0.57
52-Week Price Change -56.84%
50-Day Moving Average 7.99
200-Day Moving Average 11.8
Relative Strength Index (RSI) 20.6
Average Volume (20 Days) 408.68K

Income Statement

In the last 12 months, Enanta Pharmaceuticals had revenue of 67.64M and earned -116.05M in profits. Earnings per share was -5.48.

Revenue 67.64M
Gross Profit 67.64M
Operating Income -121.69M
Net Income -116.05M
EBITDA -104.51M
EBIT -121.69M
Earnings Per Share (EPS) -5.48
Full Income Statement

Balance Sheet

The company has 37.23M in cash and 55.47M in debt, giving a net cash position of -18.23M.

Cash & Cash Equivalents 37.23M
Total Debt 55.47M
Net Cash -18.23M
Retained Earnings -323.04M
Total Assets 376.65M
Working Capital 242.32M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -78.76M and capital expenditures -17.95M, giving a free cash flow of -96.71M.

Operating Cash Flow -78.76M
Capital Expenditures -17.95M
Free Cash Flow -96.71M
FCF Per Share -4.57
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -179.92% and -171.58%.

Gross Margin 100%
Operating Margin -179.92%
Pretax Margin -174.15%
Profit Margin -171.58%
EBITDA Margin -154.52%
EBIT Margin -179.92%
FCF Margin -142.99%

Dividends & Yields

ENTA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -112.76%
FCF Yield -93.91%
Dividend Details

Analyst Forecast

The average price target for ENTA is $19, which is 290.9% higher than the current price. The consensus rating is "Buy".

Price Target $19
Price Target Difference 290.9%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score -0.9
Piotroski F-Score 3